Program Virtual Hebon Congress

12 and 13 November 2020

Thursday November 12 2020

10:00-10:15 ***Welcome***
P. Devilee: Chair Hebon Steering Group

Session 1 – RRSO

10:15-10:35 M.P. Steenbeek: *Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in women with a BRCA1/2 pathogenic variant (TUBA study): a prospective multicentre preference trial*

10:35-10:55 I.A.S. Stroot: *Inter- and intra-observer variability in the assessment of muscle mass with the whole body DEXA scan*

10:55-11:15 M.H.D. van Bommel: *Evaluation of a Patient Decision Aid for Risk Reducing Surgery in premenopausal BRCA1/2 mutation carriers*

Session 2 – Genetics

11:15-11:35 A. Hollestelle: *The genomic landscape of breast cancers from CHEK2 c.1100delC mutation carriers*

11:35-11:55 M. Vreeswijk: *CRAFT: Cancer Risk Assessment through Functional Testing of variants in BRCA1, BRCA2 and PALB2*

11:55-12:00 *Closing session 1 and 2 - P. Devilee*

Session 3 – Personalised risk prediction

15:00-15:20 R. de Groot: *Routine recruitment and data acquisition: the Hebon Infra project*

15:20-15:40 Xin Yang: *Development of a Comprehensive Risk Prediction Model for BRCA1 and BRCA2 mutation carriers – TRANsIBCCS*

15:40-16:05 G. Evans: *What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme?*

16:05-16:30 L.J. van 't Veer: *The WISDOM Study: breaking the deadlock in the breast cancer screening debate*

16:30-16:55 *Future of personalised risk prediction: a discussion*

16:55-17:00 *Closing session 3 - P. Devilee*

Friday November 13 2020

Session 4 – Mainstreaming genetic services

10:00-10:20 N. Hoogerbrugge: *Tumor-First-workflow: Nationwide Implementation of Ovarian Cancer Heredity Prescreening to stratify both Genetic Testing and Treatment Options*

10:20-10:40 K. Bokkers: *First experiences of oncologic surgeons, medical oncologists and nurse specialists with a mainstreaming approach for germline genetic testing for patients with breast cancer*

Session 5 – Risk communication and management

10:40-11:00 N.M. Medendorp: *Discussing uncertainty about multigene panel testing: different manners, different outcomes?*

11:00-11:20 M.L. Haadsma: *Informing family members about predisposition for hereditary cancer: results of a proactive and personalized approach*

11:20-11:40 M. Hooning: *Prognosis of T1 breast cancer in BRCA1/2 mutation carriers: is screening beneficial?*

11:40-12:00 M.M.A. Tilanus-Linthorst: *MRI breast screening for women with ≥20% lifetime risk is cost-effective in Europe and preferred by most women the Famrisc trial shows*

12:00-12:05 ***Closing***
P. Devilee: Chair Hebon Steering Group